Skip to content

Arrowhead Pharmaceuticals

US · ARWR #1569 by market cap Listed 1970
41.37 -2.28 -5.22%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 43.25 -0.92%
After-hours 41.40 +0.07%
Overnight 43.00 -1.49%
89.5941.3741.372026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ARWR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -22.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 99.6% Better than 99%
Operating margin -156.9% Better than 6%
Net margin -160.6% Better than 6%
Return on equity -280.5% Better than 2%
Return on invested capital -73.2% Better than 3%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -52.5% Better than 5%
6-month return -44.8% Better than 10%
12-month return (ex latest month) 44.3% Better than 80%
Distance below 52-week high 56.7% Better than 13%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.1x Better than 82%
Debt to assets 57.5% Better than 10%
Interest coverage -6.7x Better than 15%
Free cash flow / net income 236.9% Better than 81%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 90.9% Better than 74%
Upside to average target 157.7% Better than 91%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -13.42%
1M -29.79%
3M -52.70%
6M -46.37%
YTD -37.69%
1Y +8.61%
3Y +43.15%
5Y -41.82%

Key statistics

Price & volume

Prev close
43.65
Open
43.15
Day range
41.17 - 44.80
Avg price
42.12
Volume
3.91M
Turnover
164.55M
Amplitude
8.31%
52-week range
40.43 - 95.49

Valuation

P/E
-8.10
P/E (TTM)
-8.10
P/B
116.21
EPS
-5.11
Net profit
-722.39M
Net assets
50.33M

Share structure

Market cap
5.85B
Float cap
5.08B
Shares out
141.37M
Float shares
122.91M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 2% of range
40.43 95.49

56.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-18.78M net over the window

Short interest

Shares short
11.58M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Arrowhead Pharmaceuticals (ARWR)?

Arrowhead Pharmaceuticals last traded at 41.37. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Arrowhead Pharmaceuticals's market cap?

About 5.85B.

What is the P/E ratio of Arrowhead Pharmaceuticals?

The trailing twelve-month P/E is -8.10. The Valuation tab shows it against the stock's own five-year range.

Does Arrowhead Pharmaceuticals pay a dividend?

Arrowhead Pharmaceuticals does not currently pay a regular dividend.

Is Arrowhead Pharmaceuticals a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 106.63, which implies 157.7% upside from the current price. This is not investment advice.

What is Arrowhead Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Arrowhead Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arrowhead Pharmaceuticals discussion 0 comments

Add a comment